No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FSM240517P7500
- 2.40
- 0.000.00%
15min DelayTrading May 13 10:17 ET
0.00High0.00Low
0.00Open2.40Pre Close0 Volume2 Open Interest7.50Strike Price0.00Turnover162.87%IV-0.10%PremiumMay 17, 2024Expiry Date2.35Intrinsic Value100Multiplier3DDays to Expiry0.06Time Value100Contract SizeAmericanOptions Type-0.9906Delta0.0431Gamma2.19Leverage Ratio-0.0012Theta-0.0003Rho-2.17Eff Leverage0.0001Vega
Intraday
- 5D
- 1D
News
Fortuna Silver (NYSE:FSM): Undervalued Despite Surging Demand for Precious Metals
Fortuna Silver (FSM) Q1 Earnings Top Estimates, Revenues Up Y/Y
Fortuna Silver Mines Inc. FSM reported first-quarter 2024 adjusted earnings per share of 9 cents, which beat the Zacks Consensus Estimate of 3 cents by a solid margin of 200%.
Fortuna Silver Mines Inc Price Target Raised to C$8.00/Share From C$6.50 by BMO Capital Markets
Fortuna Silver Mines Inc Price Target Raised to C$8.00/Share From C$6.50 by BMO Capital Markets
Fortuna Silver Mines Inc. (NYSE:FSM) Q1 2024 Earnings Call Transcript
Fortuna Silver Mines First Quarter 2024 Earnings: EPS: US$0.086 (Vs US$0.037 in 1Q 2023)
Express News | NYSE Order Imbalance 51955.0 Shares on Sell Side
Comments
1
$Fortuna Silver Mines(FSM.US$ I made my entry into this one today,think good longterm invrstment
2
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
10
Read more